Turkey tail mushrooms have become increasingly popular in recent years, both for their culinary uses and purported health benefits. However one question that often comes up is whether turkey tail mushrooms are psychedelic.
The short answer is no – turkey tail mushrooms do not contain any compounds that produce psychedelic effects However, their unique appearance has led some people to speculate that they might have hallucinogenic properties. In this article, we’ll explore what makes a mushroom psychedelic, examine the compounds found in turkey tail mushrooms, and explain why they do not cause a psychedelic experience
What Makes a Mushroom Psychedelic?
Psychedelic mushrooms contain compounds called psilocybin and psilocin. When ingested these substances interact with serotonin receptors in the brain leading to altered thinking, spiritual experiences, perceptual distortions, and visual hallucinations. The most well-known psychedelic mushrooms are psilocybe cubensis, commonly known as “magic mushrooms.”
Other psychoactive compounds found in certain mushrooms include muscimol in Amanita muscaria (fly agaric) and ibotenic acid in A. pantherina (panther cap). These produce intoxicating effects, but are not considered true psychedelics.
So in order for a mushroom to be psychedelic, it must contain one of these mind-altering substances like psilocybin or muscimol. Simply having an unusual or trippy appearance does not make a mushroom psychedelic.
Compounds in Turkey Tail Mushrooms
Turkey tail mushrooms contain a variety of beneficial compounds, including polysaccharides, triterpenoids, and antioxidants. The two main active constituents are:
-
Polysaccharide-K (PSK): This polysaccharide complex enhances immune function and may help fight cancer.
-
Polysaccharide-peptide (PSP): Another immuno-modulating polysaccharide that also exhibits anti-tumor properties.
In addition, turkey tail mushrooms contain ergosterol, coumarins, and trace minerals like zinc, potassium, and selenium.
Noticeably absent from this list are psilocybin, psilocin, muscimol, ibotenic acid, or any other compounds known to produce psychedelic effects.
While PSK and PSP have been shown to provide health benefits, there is no evidence that they alter consciousness or create a psychedelic experience.
The Origins of the Psychedelic Myth
So if turkey tail mushrooms don’t actually contain any psychedelics, where did the misconception come from? A few factors may be at play:
-
Unique appearance – With their concentric rings of earthy colors, turkey tail mushrooms do have a visually striking look. It’s not hard to imagine them having strange effects.
-
Association with psilocybin mushrooms – Turkey tail mushrooms and psilocybin mushrooms both belong to the fungal phylum Basidiomycota. Their taxonomic relationship may falsely imply similarities.
-
Name confusion – The whimsical name “turkey tail” sounds like it could denote a psychedelic mushroom. This may lead to accidental association with psychoactive species.
-
Wishful thinking – Some people desire or expect turkey tail mushrooms to be psychedelic. But scientific analysis reveals no basis for this belief.
While it’s an alluring idea, turkey tail mushrooms simply do not contain any compounds capable of inducing a psychedelic experience. Consuming them will provide no hallucinatory or perceptual effects.
Potential Benefits of Turkey Tail Mushrooms
Though not psychedelic, turkey tail mushrooms have many evidence-based benefits:
- May improve immune system function
- Contains antioxidants that reduce oxidative stress
- Anti-inflammatory effects that may relieve joint pain
- Anti-tumor and cancer-fighting properties
- Supports gut microbiome diversity
- Antiviral activity against HPV and other viruses
- Cardioprotective effects that support heart health
- May boost cognition and brain function
The scientifically proven benefits of turkey tail mushrooms offer plenty of motivation to add them to your diet or supplement routine. Just don’t expect any psychedelic properties.
Experiencing Turkey Tail Mushrooms Safely
Turkey tail mushrooms are classified as food-grade mushrooms with GRAS (Generally Recognized as Safe) status in the U.S. When consuming them as food or taking supplements, potential side effects are very mild. Some people report temporary digestive upset, especially at higher doses.
There are no known contraindications or interactions with medications. However, turkey tail extracts may enhance immune system activity, so they should be avoided by anyone with autoimmune diseases.
Always select high-quality organic mushroom products from reputable companies. Dosages between 500 mg to 3 grams per day seem to be both safe and effective.
It’s perfectly fine to get creative and whimsical with how you describe the psychedelic appearance of turkey tail mushrooms. But rest assured that consuming or using them as supplements will not make you hallucinate or trip out. Their health effects are strongly supported by science, even if their far-out aesthetics have more to do with imagination than pharmacology.
Frequently Asked Questions
Why do some people think turkey tail mushrooms are psychedelic?
The colorful, concentric pattern on turkey tail mushroom caps resembles a psychedelic experience. Some people falsely assume the appearance indicates psychedelic compounds. In reality, the mushroom contains no psilocybin, psilocin or other psychedelics.
What compounds are responsible for the psychedelic effects in mushrooms?
Psilocybin and psilocin are the main psychoactive compounds in “magic mushrooms.” Muscimol and ibotenic acid also have mind-altering effects. Turkey tail mushrooms contain polysaccharides but no known psychedelics.
Can you get high or trip from eating turkey tail mushrooms?
No, it is not possible to get high, hallucinate or experience psychedelic effects from consuming turkey tail mushroom products. They do not contain any pharmacologically active psychotropic compounds.
Are any mushrooms with rings psychedelic?
No, the presence of concentric rings or other radial patterning does not indicate psychedelic compounds. The chemicals responsible for visual effects are not correlated with any visible mushroom structures. Only specific psilocybin/psilocin content is psychedelic.
What are the benefits of turkey tail mushrooms?
Turkey tail mushrooms have demonstrated immune-enhancing, anti-inflammatory, antiviral, anticancer, cardioprotective and neuroprotective benefits. They support health without any psychedelic properties.
Dosing Turkey tail mushroom contains polysaccharide krestin (PSK) and polysaccharide peptide (PSP). Some
Ando, T. , Mastuda, Y. , Matsunaga, K. , Fujii, T. , Yoshikumi, C. , and Nomoto, K. [Effect of PSK on the recovery of macrophage function in tumor-bearing mice]. Gan To Kagaku Ryoho 1984;11(4):827-834. View abstract.
Chung, C. H. , Go, P. , and Chang, K. H. PSK immunotherapy in cancer patients–a preliminary report. Zhonghua Min Guo. Wei Sheng Wu Ji. Mian. Yi. Xue. Za Zhi. 1987;20(3):210-216. View abstract.
Ebina, T. and Murata, K. [Antitumor effect of intratumoral administration of BRM: inhibition of tumor cell invasion in vitro]. Gan To Kagaku Ryoho 1995;22(11):1626-1628. View abstract.
Ebina, T. and Murata, K. Antitumor effect of PSK at a distant site: tumor-specific immunity and combination with other chemotherapeutic agents. Jpn. J Cancer Res 1992;83(7):775-782. View abstract.
Fujiwara, S. , Suzumori, K. , Yasui, Y. , Yamamoto, T. , and Yagami, Y. [The effect of immunochemotherapy with PSK in malignant tumors of the female reproductive organs]. Gan No Rinsho 1986;32(1):65-70. View abstract.
Fukuo, Y. , Terashi, A. , Hayashi, Y. , Yano, Y. , and Atarashi, J. [A clinical trial of cis-platinum (II) in combination with PSK and FT-207 in advanced stomach cancer]. Gan To Kagaku Ryoho 1985;12(4):960-965. View abstract.
Hattori, T. , Nakajima, T. , Nakazato, H. , Tanabe, T. , Kikuchi, K. , Abe, O. , Kondo, T. , Taguchi, T. , Komi, N. , Sugimachi, K. , and . Postoperative immunochemotherapy with mitomycin C, tegafur, PSK, and/or OK-432 for stomach cancer, with a focus on how the stimulation index changes after a gastrectomy. Jpn. J Surg 1990;20(2):127-136. View abstract.
Hirono, M. , Yoshinaka, K. , Matsuki, K. , Noso, Y. , Oride, M. , Toge, T. , Niimoto, M. , and Hattori, T. [Surgical treatment of Borrmann type 4 (diffuse) gastric cancer]. Gan No Rinsho 1984;30(6 Suppl):717-723. View abstract.
Ichihashi, H. , Kondo, T. , and Nakazato, H. [Results of a randomized controlled trial on the effect of Esquinon and Krestin immunotherapy as adjuvant therapy in patients with stomach cancer that had been surgically removed and was found to be cancer-free—7-year survival] (Cooperative Study Group for Cancer Immunochemotherapy, Tokai Gastrointestinal Oncology Group). Gan To Kagaku Ryoho 1987;14(9):2758-2766. View abstract.
Ikeda, T. , Sakai, T. , Suito, T. , and Kosaki, G. [Evaluation of postoperative immunochemotherapy in lung cancer]. Gan To Kagaku Ryoho 1986;13(4 Pt 1):1044-1049. View abstract.
Ikuzawa, M. , Matsunaga, K. , Nishiyama, S. , Nakajima, S. , Kobayashi, Y. , Andoh, T. , Kobayashi, A. , Ohhara, M. , Ohmura, Y. , Wada, T. , and . Fate and distribution of an antitumor protein-bound polysaccharide PSK (Krestin). Int J Immunopharmacol 1988;10(4):415-423. View abstract.
Imaizumi, M. , Kondo, T. , Kamei, H. , and Ichihashi, H. [Cooperative studies on surgical adjuvant immunochemotherapy for prevention of postoperative recurrence of gastric cancer]. Gan To Kagaku Ryoho 1984;11(1):60-68. View abstract.
Imaizumi, M. , Kondo, T. , Kamei, H. , and Ichihashi, H. [Cooperative study on surgical adjuvant immunochemotherapy for prevention of postoperative recurrence of gastric cancer (II). The Ministry of Health and Welfare is funding a cooperative study group on surgical adjuvant immunochemotherapy for preventing the return of gastric cancer after surgery (Kondos group). Gan To Kagaku Ryoho 1990;17(12):2397-2403. View abstract.
Ito, K. , Nakazato, H. , Koike, A. , Takagi, H. , Saji, S. , Baba, S. , Mai, M. , Sakamoto, J. , and Ohashi, Y. Long-term effect of 5-fluorouracil enhanced by intermittent administration of polysaccharide K after curative resection of colon cancer. A randomized controlled trial for 7-year follow-up. Int. J Colorectal Dis 2004;19(2):157-164. View abstract.
Kanoh, T. , Matsunaga, K. , Saito, K. , and Fujii, T. Suppression of in vivo tumor-induced angiogenesis by the protein-bound polysaccharide PSK. In Vivo 1994;8(2):247-250. View abstract.
Kato, H. , Yokoe, N. , Takemura, S. , Yoshikawa, T. , Furukawa, Y. , and Kondo, M. Effect of a protein-bound polysaccharide PS-K on the complement system. Res Exp. Med (Berl) 1983;182(2):85-94. View abstract.
Koda, K. , Miyazaki, M. , Sarashina, H. , Suwa, T. , Saito, N. , Suzuki, M. , Ogawa, K. , Watanabe, S. , Kodaira, S. , and Nakazato, H. A randomized controlled trial of postoperative adjuvant immunochemotherapy for colorectal cancer with oral medicines. Int J Oncol 2003;23(1):165-172. View abstract.
Kojima, J. , Kamata, T. , and Monna, T. [Evaluation of immunochemotherapy in patients with primary liver cancer. Osaka Research Society for Liver, Gallbladder and Pancreas]. Gan To Kagaku Ryoho 1987;14(1):179-187. View abstract.
Kondo, M. , Kato, H. , Yokoe, N. , Matsumura, N. , Hotta, T. , and Masuda, M. Activation of the complement by immunostimulants, BCG, OK-432 (Picibanil), and PS-K (Krestin) in vitro. Gann 1978;69(5):699-702. View abstract.
Kudo, S. , Tanaka, J. , Kashida, H. , Tamegai, Y. , Endo, S. , and Yamano, H. O. Effectiveness of immunochemotherapy with PSK, a protein-bound polysaccharide, in colorectal cancer and changes of tumor marker. Oncol Rep. 2002;9(3):635-638. View abstract.
Matsunaga, K. , Iijima, H. , and Kobayashi, H. Introducing the protein-bound polysaccharide PSK to newborn animals makes adult animals more resistant to being challenged with syngeneic tumor cells and lowers the number of precancerous lesions in the colon caused by azoxymethane. Cancer Epidemiol. Biomarkers Prev. 2000;9(12):1313-1322. View abstract.
Mitomi, T. , Tsuchiya, S. , Iijima, N. , Aso, K. , Suzuki, K. , Nishiyama, K. , Amano, T. , Takahashi, T. , Murayama, N. , Oka, H. , and . [Randomized controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer. The Cooperative Study Group of Surgical Adjuvant Immunochemotherapy for Cancer of Colon and Rectum]. Gan To Kagaku Ryoho 1989;16(6):2241-2249. View abstract.
Morinaga, H. , Tazawa, K. , Tagoh, H. , Muraguchi, A. , and Fujimaki, M. An in vivo study of hepatic and splenic interleukin-1 beta mRNA expression following oral PSK or LEM administration. Jpn. J Cancer Res 1994;85(12):1298-1303. View abstract.
Nagao, T. , Komatsuda, M. , Yamauchi, K. , Nozaki, H. , Watanabe, K. , and Arimori, S. Chemoimmunotherapy with Krestin in acute leukemia. Tokai J Exp Clin Med 1981;6(2):141-146. View abstract.
Nakajima, T. , Inokuchi, K. , Hattori, T. , Inoue, K. , Taguchi, T. , Kondo, T. , Abe, O. , Kikuchi, K. , Tanabe, T. , and Ogawa, N. [A multi-institutional study on postoperative adjuvant immunochemotherapy of gastric cancer]. Gan To Kagaku Ryoho 1985;12(9):1850-1863. View abstract.
Nakajima, T. , Inokuchi, K. , Hattori, T. , Inoue, K. , Taguchi, T. , Kondou, T. , Abe, O. , Kikuchi, K. , Tanabe, T. , and Ogawa, N. [Multi-institutional cooperative study of adjuvant immunochemotherapy in gastric cancer–five-year survival rate]. Gan To Kagaku Ryoho 1989;16(4 Pt 1):799-806. View abstract.
Nakazato, H. , Koike, A. , Ichihashi, H. , Saji, S. , Danno, M. , and Ogawa, N. [A randomized controlled trial by the cooperative study group looked at the effects of adjuvant immunochemotherapy using krestin and 5-FU on gastric cancer patients who had major surgery (first report)]. Study Group of Immuno-chemotherapy with PSK for Gastric Cancer]. Gan To Kagaku Ryoho 1989;16(8 Pt 1):2563-2576. View abstract.
Niimoto, M. , Hattori, T. , Tamada, R. , Sugimachi, K. , Inokuchi, K. , and Ogawa, N. Postoperative adjuvant immunochemotherapy with mitomycin C, futraful and PSK for gastric cancer. An analysis of data on 579 patients followed for five years. Jpn. J Surg 1988;18(6):681-686. View abstract.
Nishiwaki, Y. , Furuse, K. , Fukuoka, M. , Ota, M. , Niitani, H. , Asakawa, M. , Nakai, H. , Sakai, S. , and Ogawa, N. [A randomized controlled study of PSK combined immuno-chemotherapy for adenocarcinoma of the lung. The Advanced Lung Cancer Immuno-chemotherapy Study Group]. Gan To Kagaku Ryoho 1990;17(1):131-136. View abstract.
Nomoto, K. , Tsuru, S. , Awane, Y. , Kamei, H. , Ishibiki, H. , Sekiguchi, M. , Tamada, R. , Toge, T. , and Nakajima, T. [Changes in nonspecific suppressor factors in the serum of gastric cancer patients after surgery and immunochemotherapy]. Gan To Kagaku Ryoho 1986;13(3 Pt 1):458-463. View abstract.
Ogoshi, K. , Satou, H. , Isono, K. , Mitomi, T. , Endoh, M. , and Sugita, M. Possible predictive markers of immunotherapy in esophageal cancer: retrospective analysis of a randomized study. The Cooperative Study Group for Esophageal Cancer in Japan. Cancer Invest 1995;13(4):363-369. View abstract.
Ogoshi, K. , Tajima, T. , Mitomi, T. , Makuuchi, H. , and Tsuji, K. HLA-A2 antigen status predicts metastasis and response to immunotherapy in gastric cancer. Cancer Immunol Immunother. 1997;45(1):53-59. View abstract.
Ohmura, Y. , Matsunaga, K. , Motokawa, I. , Sakurai, K. , and Ando, T. PSK, a protein-bound polysaccharide, protects against Candida albicans infection in mice with tumors by working through Th1 cells. Cancer Biother. Radiopharm. 2003;18(5):769-780. View abstract.
Ohno, R. , Yamada, K. , Masaoka, T. , Ohshima, T. , Amaki, I. , Hirota, Y. , Horikoshi, N. , Horiuchi, A. , Imai, K. , Kimura, I. , and . A randomized trial of chemoimmunotherapy of acute nonlymphocytic leukemia in adults using a protein-bound polysaccharide preparation. Cancer Immunol Immunother. 1984;18(3):149-154. View abstract.
Ohwada, S. , Ikeya, T. , Yokomori, T. , Kusaba, T. , Roppongi, T. , Takahashi, T. , Nakamura, S. , Kakinuma, S. , Iwazaki, S. , Ishikawa, H. , Kawate, S. , Nakajima, T. , and Morishita, Y. A randomized controlled study looked at the effects of adding oral Tegafur/Uracil plus PSK to immunochemotherapy in people with stage II or III colorectal cancer. Br. J Cancer 3-8-2004;90(5):1003-1010. View abstract.
Ohwada, S. , Kawate, S. , Ikeya, T. , Yokomori, T. , Kusaba, T. , Roppongi, T. , Takahashi, T. , Nakamura, S. , Kawashima, Y. , Nakajima, T. , and Morishita, Y. A randomized, controlled trial of protein-bound polysaccharide K and tegafur uracil as additional treatment for people with stage II or III colorectal cancer Dis Colon Rectum 2003;46(8):1060-1068. View abstract.
Ohwada, S. , Ogawa, T. , Makita, F. , Tanahashi, Y. , Ohya, T. , Tomizawa, N. , Satoh, Y. , Kobayashi, I. , Izumi, M. , Takeyoshi, I. , Hamada, K. , Minaguchi, S. , Togo, Y. , Toshihiko, T. , Koyama, T. , and Kamio, M. Protein-bound polysaccharide K plus tegafur/uracil is helpful for people with stage II or III colorectal cancer. This study looks at immunological parameters. Oncol. Rep 2006;15(4):861-868. View abstract.
Pang, Z. J. , Chen, Y. , Zhou, M. , and Wan, J. Effect of polysaccharide krestin on glutathione peroxidase gene expression in mouse peritoneal macrophages. Br. J Biomed Sci 2000;57(2):130-136. View abstract.
Sakamoto, J. , Koike, A. , Saji, S. , Teramukai, S. , Ohashi, Y. , and Nakazato, H. An early serum immunosuppressive acidic protein (IAP) test was used to figure out how likely it was that someone would get stomach cancer. The test looked at the threshold level statistically and how the biological response modifier PSK affected the results. Surg Today 1992;22(6):530-536. View abstract.
Sakamoto, J. , Morita, S. , Oba, K. , Matsui, T. , Kobayashi, M. , Nakazato, H. , and Ohashi, Y. The effectiveness of adding polysaccharide K to immunochemotherapy for people whose colorectal cancer has been removed and was found to be curable: a meta-analysis of centrally randomized controlled clinical trials Cancer Immunol. Immunother. 2006;55(4):404-411. View abstract.
Sakamoto, J. , Nakazato, H. , Ichihashi, H. , Koike, A. , Ohashi, Y. , Tamura, H. , Fujii, T. , and Ogawa, N. [The minimization method in a medium size clinical trial. Study of immunochemotherapy with PSK in gastric cancer]. Gan To Kagaku Ryoho 1988;15(6):1935-1942. View abstract.
Shibata, M. , Nezu, T. , Kanou, H. , Nagata, Y. , Kimura, T. , Takekawa, M. , Ando, K. , and Fukuzawa, M. Immunomodulatory effects of low dose cis-Diaminedichloroplatinum (cisplatin) combined with UFT and PSK in patients with advanced colorectal cancer. Cancer Invest 2002;20(2):166-173. View abstract.
Sugiyama, Y. , Saji, S. , Miya, K. , Fukada, D. , Umemoto, T. , Kunieda, K. , Takao, H. , Kato, M. , and Kawai, M. [Locoregional therapy for liver metastases of colorectal cancer]. Gan To Kagaku Ryoho 1996;23(11):1433-1436. View abstract.
Takahashi, Y. , Mai, M. , and Nakazato, H. Preoperative CEA and PPD values as prognostic factors for immunochemotherapy using PSK and 5-FU. Anticancer Res 2005;25(2B):1377-1384. View abstract.
Takashima, S. , Kinami, Y. , and Miyazaki, I. [Clinical effect of postoperative adjuvant immunochemotherapy with the FT-207 suppository and PSK in colorectal cancer patients. Colorectal Cancer Chemotherapy Group in Hokuriku]. Gan To Kagaku Ryoho 1988;15(8):2229-2236. View abstract.
Tamada, R. , Inokuchi, K. , Hattori, T. , Inoue, K. , Taguchi, T. , Kondo, T. , Abe, O. , Kikuchi, K. , Tanabe, T. , Nakajima, T. , and . [A multi-institutional study on postoperative adjuvant immunochemotherapy of gastric cancer (II)]. Gan To Kagaku Ryoho 1987;14(3 Pt 1):716-722. View abstract.
Toge, T. and Yamaguchi, Y. Protein-bound polysaccharide increases survival in resected gastric cancer cases stratified with a preoperative granulocyte and lymphocyte count. Oncol. Rep 2000;7(5):1157-1161. View abstract.
Tsujitani, S. , Kakeji, Y. , Orita, H. , Watanabe, A. , Kohnoe, S. , Baba, H. , Anai, H. , Maehara, Y. , and Sugimachi, K. Postoperative adjuvant immunochemotherapy and infiltration of dendritic cells for patients with advanced gastric cancer. Anticancer Res 1992;12(3):645-648. View abstract.
Albert KS, et al. Pharmacokinetic evaluation of a drug interaction between kaolin-pectin and clindamycin. J Pharm Sci 1978 67:1579-82. View abstract.
Barros AB, Ferrão J, Fernandes T. A safety assessment of Coriolus versicolor biomass as a food supplement. Food Nutr Res 2016;60:29953. View abstract.
Chan SL, Yeung JH. How polysaccharide peptide (PSP) from Coriolus versicolor changes the way cyclophosphamide works in rats and how it kills HepG2 cells Food Chem Toxicol 2006;44:689-94. View abstract.
Chay WY, Tham CK, Toh HC, et al. Coriolus versicolor (Yunzhi) is used as a treatment for advanced hepatocellular carcinoma in people whose livers don’t work well or who can’t handle standard treatment. J Altern Complement Med 2017;23(8):648-52. View abstract.
Collins RA, Ng TB. Polysaccharopeptide from Coriolus versicolor has potential for use against human immunodeficiency virus type 1 infection. Life Sci 1997;60:PL383-7. View abstract.
Cortés Bordoy J, de Santiago GarcÃa J, Agenjo González M, et al. Effect of a multi-ingredient Coriolus-versicolor-based vaginal gel in women with HPV-dependent cervical lesions: The papilobs real-life prospective study. Cancers (Basel) 2023;15(15):3863. View abstract.
Criscuolo AA, Sesti F, Piccione E, et al. A study that looked back at past data found that a vaginal gel made from Coriolus versicolor helped women with a high-risk HPV infection in their cervix and uterus. Adv Ther 2021;38(2):1202-1211. View abstract.
Dong Y, Kwan CY, Chen ZN, et al. Antitumor effects of a refined polysaccharide peptide fraction isolated from Coriolus versicolor: in vitro and in vivo studies. Res Commun Mol Pathol Pharmacol 1996;92:140-8. View abstract.
Dong Y, Yang MM, Kwan CY. Tetrandrine and a peptide from coriolus versicolor, which comes from Chinese medicinal herbs, stopped the growth of HL-60 cells in the lab. Life Sci 1997;60:PL135-40. View abstract.
Eliza WL, Fai CK, Chung LP. Efficacy of Yun Zhi (Coriolus versicolor) on survival in cancer patients: systematic review and meta-analysis. Recent Pat Inflamm Allergy Drug Discov 2012;6(1):78-87. View abstract.
Fukushima M. Adjuvant therapy of gastric cancer: the Japanese experience. Semin Oncol 1996;23:369-78. View abstract.
Gil-Antuñano SP, Serrano Cogollor L, López DÃaz AC, et al. A part of the PALOMA study looked at how well a coriolus versicolor-based vaginal gel worked on women older than 40 who had human papillomavirus. J Pers Med 2022;12(10):1559. View abstract.
Go P, Chung CH. Adjuvant PSK immunotherapy in patients with carcinoma of the nasopharynx. J Int Med Res 1989;17:141-9. View abstract.
Gong S, Zhang HQ, Yin WP, et al. Involvement of interleukin-2 in analgesia produced by Coriolus versicolor polysaccharide peptides. Chung Kuo Yao Li Hsueh Pao 1998;19:67-70. View abstract.
Harada M, Matsunaga K, Oguchi Y, et al. Giving PSK to mice by mouth can improve their weakened anti-tumor CD4 T-cell response in gut-associated lymphoid tissue (GALT). These mice do not have any specific pathogens. Int J Cancer 1997;70:362-72. View abstract.
Hayakawa K, Mitsuhashi N, Saito Y, et al. Effect of Krestin as adjuvant treatment following radical radiotherapy in non-small cell lung cancer patients. Cancer Detect Prev 1997;21:71-7. View abstract.
Hor SY, Ahmad M, Farsi E, Lim CP, Asmawi MZ, Yam MF. Acute and subchronic oral toxicity of Coriolus versicolor standardized water extract in Sprague-Dawley rats. J Ethnopharmacol 2011;137(3):1067-76. View abstract.
Iino Y, Yokoe T, Maemura M, et al. Immunochemotherapies versus chemotherapy as adjuvant treatment after curative resection of operable breast cancer. Anticancer Res 1995;15:2907-11. View abstract.
Jin M, Zhou W, Jin C, et al. Anti-inflammatory activities of the chemical constituents isolated from Trametes versicolor. Nat Prod Res 2019;33(16):2422-5. View abstract.
Kanoh T, Saito K, Matsunaga K, et al. It is better to use a monoclonal antibody and the protein-bound polysaccharide PSK together to fight tumors in mice that have a human cancer cell line implanted. In Vivo 1994;8:241-5. View abstract.
Kim HS, Kacew S, Lee BM. In vitro chemopreventive effects of plant polysaccharides (Aloe barbadensis miller, Lentinus edodes, Ganoderma lucidum and Coriolus versicolor). Carcinogenesis 1999;20:1637-40. View abstract.
Kobayashi H, Matsunaga K, Oguchi Y. Antimetastatic effects of PSK (Krestin), a protein-bound polysaccharide obtained from basidiomycetes: an overview. Cancer Epidemiol Biomarkers Prev 1995;4:275-81. View abstract.
Kondo T, Sakamoto J, Nakazato H. Changing immunochemotherapy for advanced gastric cancer: a random comparison of carbazilquinone and PSK to carbazilquinone in people who had a successful gastric resection Biotherapy 1991;3:287-95. View abstract.
Maehara Y, Inutsuka S, Takeuchi H, et al. Postoperative PSK and OK-432 immunochemotherapy for patients with gastric cancer. Cancer Chemother Pharmacol 1993;33:171-5. View abstract.
Meng F, Lin Y, Hu L, Feng W, Su P, Wu L. The therapeutic effect of Coriolus versicolor fruiting body on STZ-induced ICR diabetic mice. J Healthc Eng 2022;2022:7282453. View abstract.
Mitomi T, Tsuchiya S, Iijima N, et al. Randomized, controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer. The Cooperative Study Group of Surgical Adjuvant Immunochemotherapy for Cancer of Colon and Rectum (Kanagawa). Dis Colon Rectum 1992;35:123-30. View abstract.
Mizutani Y, Yoshida O. The protein-bound polysaccharide PSK (krestin) turns on cytotoxic lymphocytes that attack new autologous tumor cells and the T24 human urinary bladder transitional carcinoma cell line in people who have UTIs. J Urol 1991;145:1082-7. View abstract.
Morimoto T, Ogawa M, Orita K, et al. A 5-year study from the Nishinihon Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Cancer (ACETBC) of Japan compared chemoendocrine therapy, chemotherapy, and immunotherapy for women with stage II breast cancer after surgery. Eur J Cancer 1996;32A:235-42. View abstract.
Nakazato H, Koike A, Saji S, et al. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer. Lancet 1994;343:1122-6. View abstract.
Ng TB, Chan WY. The polysaccharopeptide from the mushroom Coriolus versicolor can relieve pain but doesn’t hurt the reproductive or embryonic development of female mice. Gen Pharmacol 1997;29:269-73. View abstract.
Ng TB. A review of research on the protein-bound polysaccharide (polysaccharopeptide, PSP) from the mushroom Coriolus versicolor (Basidiomycetes: Polyporaceae). Gen Pharmacol 1998;30:1-4. View abstract.
Nikolic M, Lazarevic N, Novakovic J, et al. Characterization, in vitro biological activity and in vivo cardioprotective properties of Trametes versicolor (L. :Fr. ) quél. heteropolysaccharides in a rat model of metabolic syndrome. Pharmaceuticals (Basel) 2023;16(6):787. View abstract.
Nio Y, Tsubono M, Tseng CC, et al. Immunomodulation by orally administered protein-bound polysaccharide PSK in patients with gastrointestinal cancer. Biotherapy 1992;4:117-28. View abstract.
Ogoshi K, Satou H, Isono K, et al. Immunotherapy for esophageal cancer. A randomized trial in combination with radiotherapy and radiochemotherapy. Cooperative Study Group for Esophageal Cancer in Japan. Am J Clin Oncol 1995;18:216-22. View abstract.
Palacios S, Losa F, Dexeus D, Cortés J. The effects of a vaginal gel containing Coriolus versicolor on cervical epithelization, vaginal microbiota, and vaginal health were studied in women who did not have any symptoms. BMC Womens Health 2017;17(1):21. View abstract.
Qian ZM, Xu MF, Tang PL. Polysaccharide peptide (PSP) restores immunosuppression induced by cyclophosphamide in rats. Am J Chin Med 1997;25:27-35. View abstract.
Razmovski-Naumovski V, Kimble B, Laurenti D, Nammi S, Norimoto H, Chan K. The polysaccharide peptide extract from Coriolus versicolor raised the T(max) of tamoxifen and kept the biochemical parameters of the serum the same. There were no changes in how the rat’s body used tamoxifen. Front Pharmacol 2022;13:857864. View abstract.
Serrano L, López AC, González SP, et al. Efficacy of a Coriolus versicolor-based vaginal gel in women with human papillomavirus-dependent cervical lesions: The PALOMA study. J Low Genit Tract Dis 2021;25(2):130-136. View abstract.
Sugimachi K, Maehara Y, Ogawa M, et al. Dose intensity of uracil and tegafur in postoperative chemotherapy for patients with poorly differentiated gastric cancer. Cancer Chemother Pharmacol 1997;40:233-8. View abstract.
Suto T, Fukuda S, Moriya N, et al. Clinical study of biological response modifiers as maintenance therapy for hepatocellular carcinoma. Cancer Chemother Pharmacol 1994;33 Suppl:S145-8. View abstract.
Tochikura TS, Nakashima H, Hirose K, et al. A biological response modifier, PSK, inhibits human immunodeficiency virus infection in vitro. Biochem Biophys Res Commun 1987;148:726-33. View abstract.
Toi M, Hattori T, Akagi M, et al. Randomized trial to see what happens when tamoxifen and PSK are added to chemotherapy in people with primary breast cancer 5-Year results from the Nishi-Nippon Group of the Adjuvant Chemoendocrine Therapy for Breast Cancer Organization. Cancer 1992;70:2475-83. View abstract.
Torisu M, Hayashi Y, Ishimitsu T, et al. Oral polysaccharide K (PSK) administration after curative surgery for colorectal cancer significantly extended the time without disease. Cancer Immunol Immunother 1990;31:261-8. View abstract.
Tsukagoshi S, Hashimoto Y, Fujii G, et al. Krestin (PSK). Cancer Treat Rev 1984;11:131-55. View abstract.
Wang HX, Ng TB, Liu WK, et al. The mycelia of the mushroom Coriolus versicolor and their culture medium contain polysaccharide-peptide complexes that make mouse lymphocytes and macrophages work. Int J Biochem Cell Biol 1996;28:601-7. View abstract.
Wasser SP, Weis AL. Therapeutic effects of substances occurring in higher Basidiomycetes mushrooms: a modern perspective. Crit Rev Immunol 1999;19:65-96. View abstract.
Yeung JH and Or PM. Polysaccharide peptides from Coriolus versicolor effectively stop tolbutamide 4-hydroxylation in a specific type of human CYP2C9 and in human liver microsomes that have been gathered. Phytomedicine 2011;18(13):1170-5. View abstract.
Yeung JH, Chiu LC, Ooi VE. Effect of polysaccharide peptide (PSP) on glutathione and protection against paracetamol-induced hepatotoxicity in the rat. Methods Find Exp Clin Pharmacol 1994;16:723-9. View abstract.
Yokoe T, Iino Y, Takei H, et al. HLA antigen as predictive index for the outcome of breast cancer patients with adjuvant immunochemotherapy with PSK. Anticancer Res 1997;17:2815-8. View abstract.
Zhong L, Yan P, Lam WC, et al. Natural products from Coriolus versicolor and Ganoderma lucidum that are related to cancer: a systematic review and meta-analysis of randomized controlled trials Front Pharmacol 2019;10:703. View abstract.
Select a condition to view a list of vitamins
Special Precautions and Warnings
- The way cyclophosphamide reacts with TURKEY TAIL MUSHROOMPSP, a chemical found in turkey tail mushrooms, could change how quickly the drug is flushed out of the body. This could change how well it works and make the side effects worse.
- Diabetes medicines (antidiabetes drugs) can affect the turkey tail mushroom. The turkey tail mushroom may lower blood sugar levels. If you take diabetes medicines along with turkey tail mushroom, your blood sugar might drop too low. Monitor your blood sugar closely.
- Turkey tail mushroom and tamoxifen (Nolvadex) may not work well together. Taking turkey tail mushroom with tamoxifen may change how tamoxifen works in the body or lessen its effects.
Moderate Interaction
Be cautious with this combination
- Some medicines that are changed and broken down by the liver (Cytochrome P450 2C9 (CYP2C9) substrates) interact with turkey tail mushroom. PSP is a chemical that can be found in turkey tail mushrooms. It might change how fast the liver breaks down these drugs. This might change how these medicines work and what side effects they cause.
Minor Interaction
Be watchful with this combination